218 related articles for article (PubMed ID: 16225488)
1. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin.
Yeomans ND; Lanas AI; Talley NJ; Thomson AB; Daneshjoo R; Eriksson B; Appelman-Eszczuk S; Långström G; Naesdal J; Serrano P; Singh M; Skelly MM; Hawkey CJ
Aliment Pharmacol Ther; 2005 Nov; 22(9):795-801. PubMed ID: 16225488
[TBL] [Abstract][Full Text] [Related]
2. Geographic differences in low-dose aspirin-associated gastroduodenal mucosal injury.
Iijima K; Shimosegawa T
World J Gastroenterol; 2015 Jul; 21(25):7709-17. PubMed ID: 26167071
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of Helicobacter pylori infection in duodenal ulcer and gastro-duodenal ulcer diseases in Taiwan.
Chen TS; Luo JC; Chang FY
J Gastroenterol Hepatol; 2010 May; 25(5):919-22. PubMed ID: 20074147
[TBL] [Abstract][Full Text] [Related]
4. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
Goldstein JL; Cryer B; Amer F; Hunt B
Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1167-74. PubMed ID: 17916545
[TBL] [Abstract][Full Text] [Related]
5. The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor.
Goldstein JL; Lowry SC; Lanza FL; Schwartz HI; Dodge WE
Aliment Pharmacol Ther; 2006 May; 23(10):1489-98. PubMed ID: 16669964
[TBL] [Abstract][Full Text] [Related]
6. [Development and relapse of gastroduodenal ulcer in patients taking nonsteroid anti-inflammatory drugs: effects of standard risk factors].
Karateev AE; Nasonova VA
Ter Arkh; 2008; 80(5):62-6. PubMed ID: 18590118
[TBL] [Abstract][Full Text] [Related]
7. Investigation of gastroduodenal mucosal injuries caused by low-dose aspirin therapy in patients with cerebral infarction.
Nema H; Kato M
J Gastroenterol Hepatol; 2010 May; 25 Suppl 1():S119-21. PubMed ID: 20586852
[TBL] [Abstract][Full Text] [Related]
8. Impact of upper gastrointestinal lesions in patients on low-dose aspirin therapy: preliminary study.
Kawai T; Watanabe M; Yamashina A
J Gastroenterol Hepatol; 2010 May; 25 Suppl 1():S23-30. PubMed ID: 20586861
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years.
Goldstein JL; Aisenberg J; Lanza F; Schwartz H; Sands GH; Berger MF; Pan S
Clin Ther; 2006 Mar; 28(3):340-51. PubMed ID: 16750449
[TBL] [Abstract][Full Text] [Related]
10. Low-dose aspirin-associated upper gastric and duodenal ulcers in Japanese patients with no previous history of peptic ulcers.
Kawamura N; Ito Y; Sasaki M; Iida A; Mizuno M; Ogasawara N; Funaki Y; Kasugai K
BMC Res Notes; 2013 Nov; 6():455. PubMed ID: 24215903
[TBL] [Abstract][Full Text] [Related]
11. Endoscopy in asymptomatic minidose aspirin consumers.
Niv Y; Battler A; Abuksis G; Gal E; Sapoznikov B; Vilkin A
Dig Dis Sci; 2005 Jan; 50(1):78-80. PubMed ID: 15712641
[TBL] [Abstract][Full Text] [Related]
12. Predictors of gastroduodenal erosions in patients taking low-dose aspirin.
Hart J; Hawkey CJ; Lanas A; Naesdal J; Talley NJ; Thomson AB; Yeomans ND
Aliment Pharmacol Ther; 2010 Jan; 31(1):143-9. PubMed ID: 19709095
[TBL] [Abstract][Full Text] [Related]
13. Misoprostol for small bowel ulcers in patients with obscure bleeding taking aspirin and non-steroidal anti-inflammatory drugs (MASTERS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Taha AS; McCloskey C; McSkimming P; McConnachie A
Lancet Gastroenterol Hepatol; 2018 Jul; 3(7):469-476. PubMed ID: 29754836
[TBL] [Abstract][Full Text] [Related]
14. [The epidemiology of the gastroduodenal damage induced by aspirin and other nonsteroidal anti-inflammatory drugs].
Dobrilla G; Benvenuti S; de Guelmi A
Recenti Prog Med; 1997 May; 88(5):202-11. PubMed ID: 9244954
[TBL] [Abstract][Full Text] [Related]
15. Risk and preventive factors of low-dose aspirin-induced gastroduodenal injuries: a comprehensive review.
Shiotani A; Manabe N; Kamada T; Fujimura Y; Sakakibara T; Haruma K
J Gastroenterol Hepatol; 2012 Apr; 27 Suppl 3():8-12. PubMed ID: 22486865
[TBL] [Abstract][Full Text] [Related]
16. Aspirin Use in Secondary Cardiovascular Protection and the Development of Aspirin-Associated Erosions and Ulcers.
Goldstein JL; Scheiman JM; Fort JG; Whellan DJ
J Cardiovasc Pharmacol; 2016 Aug; 68(2):121-6. PubMed ID: 27002280
[TBL] [Abstract][Full Text] [Related]
17. Relationship between continuous use of low-dose enteric-coated aspirin and gastrointestinal injuries in patients with gastrointestinal hemorrhage.
Mousavi M; Salehimarzijarani B; Dadvar Z; Jalalay NY; Valizadeh N; Sotoudeh H; Zali M
Turk J Gastroenterol; 2013; 24(2):93-8. PubMed ID: 23934454
[TBL] [Abstract][Full Text] [Related]
18. Strongly increased risk of gastric and duodenal ulcers among new users of low-dose aspirin: results from two large cohorts with new-user design.
Nguyen TNM; Sha S; Chen LJ; Holleczek B; Brenner H; Schöttker B
Aliment Pharmacol Ther; 2022 Jul; 56(2):251-262. PubMed ID: 35621052
[TBL] [Abstract][Full Text] [Related]
19. Upper gastrointestinal mucosal abnormalities and blood loss complicating low-dose aspirin and antithrombotic therapy.
Taha AS; Angerson WJ; Knill-Jones RP; Blatchford O
Aliment Pharmacol Ther; 2006 Feb; 23(4):489-95. PubMed ID: 16441469
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with gastro-duodenal disease in patients undergoing upper GI endoscopy at the Korle-Bu Teaching Hospital, Accra, Ghana.
Archampong TN; Asmah RH; Wiredu EK; Gyasi RK; Nkrumah KN
Afr Health Sci; 2016 Jun; 16(2):611-9. PubMed ID: 27605979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
